CHD1L and colorectal cancer: These inhibitors demonstrated the ability to suppress CHD1L-mediated TCF/LEF transcriptional activity, reverse EMT, and reduce cancer stem cell (CSC) stemness in colorectal cancer models, mirroring the effects observed with CHD1L knockdown.